Finanzen von Definium Therapeutics Inc (DFTX)DFTXDefinium Therapeutics Inc

Evaluating the bottom line, Definium Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.09%, provide a clear picture of how effectively DFTX converts its operational activities into shareholder value.

In the context of the broader market, DFTX competes directly with industry leaders such as TVTX and ERAS. With a market capitalization of $4.79B, it holds a significant position in the sector. When comparing efficiency, DFTX's gross margin of N/A stands against TVTX's 96.45% and ERAS's N/A. Such benchmarking helps identify whether Definium Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Definium has shown a significant increase in common stock equity, rising from $130.6 million in Q3 2025 to $918.7 million in Q2 2026, indicating strong capital growth despite ongoing losses.